张惠芳,宋洪勇,李果,何东方,陶倩

• 1:首都医科大学附属北京安贞医院心血管内科
• 2:山东第一医科大学附属中心医院心血管内科

摘要(Abstract)：

目的 比较不同临床表现的冠状动脉支架内再狭窄（ISR）患者接受药物涂层球囊（DCB）治疗后的临床结局。方法 本研究为回顾性研究，纳入了2020年5月至2022年5月在首都医科大学附属北京安贞医院确诊的508例冠状动脉ISR患者。所有患者均接受了DCB治疗。根据临床表现不同，患者被分为急性冠状动脉综合征（ACS）组（185例）和非ACS组（323例）。对所有患者进行了为期24个月的随访，主要比较两组患者在心肌梗死、靶病变血运重建（TLR）、死亡以及主要不良心血管事件（MACE）方面的发生率。结果 两组患者的基线资料比较显示，ACS组在高血压病、糖尿病和吸烟方面的比例显著高于非ACS组（均P<0.05）。此外，ACS组的B2/C型病变、长病变和中度至重度钙化病变的比例更高（均P<0.05），且置入的支架数量、长度和直径均大于非ACS组，但差异均无统计学意义（均P>0.05）。术后12个月随访结果显示，ACS组的TLR发生率（8.1%比2.5%,P=0.007）以及MACE发生率（10.3%比5.3%,P=0.047）均显著高于非ACS组；在24个月随访结束时，ACS组的TLR发生率（18.9%比10.2%,P=0.007）和MACE发生率（22.7%比14.9%,P=0.030）仍高于非ACS组，差异均有统计学意义。结论 ACS表现的ISR患者具有更高的心血管风险和复杂病变，接受DCB治疗后的TLR发生率更高。

关键词(KeyWords)： 药物涂层球囊;支架内再狭窄;急性冠状动脉综合征;临床表现;结局

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张惠芳,宋洪勇,李果,何东方,陶倩

参考文献(References)：

• [1]Ullrich H,Olschewski M,Münzel T,et al.Coronary instent restenosis:predictors and treatment[J].Dtsch Arztebl Int,2021,118(38):637-644.DOI:10.3238/arztebl.m2021.0254.
• [2]Buchanan KD,Torguson R,Rogers T,et al.In-stent restenosis of drug-eluting stents compared with a matched group of patients with de novo coronary artery stenosis[J].Am J Cardiol,2018,121(12):1512-1518.DOI:10.1016/j.amjcard.2018.02.033.
• [3]He W,Xu C,Wang X,et al.Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention[J].BMC Cardiovasc Disord,2021,21(1):435.DOI:10.1186/s12872-021-02255-4.
• [4]郝伟,赵晨,胡思宁,等.冠状动脉药物洗脱支架内再狭窄的最新研究进展[J].中国介入心脏病学杂志,2023,31(1):63-68.DOI:10.3969/j.issn.1004-8812.2023.01.010.
• [5]Zhang DM,Chen SL.Potential mechanisms of in-stent neointimal atherosclerotic plaque formation[J].J Cardiovasc Pharmacol,2021,78(3):388-393.DOI:10.1097/FJC.0000000000001059.
• [6]Nestelberger T,Kaiser C,Jeger R.Drug-coated balloons in cardiovascular disease:benefits,challenges,and clinical applications[J].Expert Opin Drug Deliv,2020,17(2):201-211.DOI:10.1080/17425247.2020.1714590.
• [7]Cho JY.Identification of risk factors influencing in-stent restenosis with acute coronary syndrome presentation[J].Chonnam Med J,2017,53(3):203-210.DOI:10.4068/cmj.2017.53.3.203.
• [8] Magalhaes MA,Minha S,Chen F,et al.Clinical presentation and outcomes of coronary in-stent restenosis across 3-stentgenerations[J].Circ Cardiovasc Interv,2014,7(6):768-776.DOI:10.1161/CIRCINTERVENTIONS.114.001341.
• [9]Shao C,Wang J,Tian J,et al.Coronary artery disease:from mechanism to clinical practice[J].Adv Exp Med Biol,2020,1177:1-36.DOI:10.1007/978-981-15-2517-9 1.
• [10]Thygesen K,Alpert JS,Jaffe AS,et al.Fourth universal definition of myocardial infarction(2018)[J].Glob Heart,2018,13(4):305-338.DOI:10.1016/j.gheart.2018.08.004.
• [11]Joshi PH,de Lemos JA.Diagnosis and management of stable angina:a review[J].JAMA,2021,325(17):1765-1778.DOI:10.1001/jama.2021.1527.
• [12]Theofilis P,Antonopoulos AS,Sagris M,et al.Silent myocardial ischemia:from pathophysiology to diagnosis and treatment[J].Biomedicines,2024,12(2):259.DOI:10.3390/biomedicines12020259.
• [13] Noll D,Kruk M,Demkow M,et al.Patterns of coronary calcification and their impact on the diagnostic accuracy of computed tomography coronary angiography[J].J Comput Assist Tomogr,2018,42(2):263-268.DOI:10.1097/RCT.0000000000000681.
• [14]Cui Y,Zeng W,Yu J,et al.Quantification of left coronary bifurcation angles and plaques by coronary computed tomography angiography for prediction of significant coronary stenosis:a preliminary study with dual-source CT[J].PLoS One,2017,12(3):e0174352.DOI:10.1371/journal.pone.0174352.
• [15]Abouelnour A,Gori T.Intravascular imaging in coronary stent restenosis:prevention,characterization,and management[J].Front Cardiovasc Med,2022,9:843734.DOI:10.3389/fcvm.2022.843734.
• [16] Schwalm T,Carlsson J,Meissner A,et al.Current treatment and outcome of coronary in-stent resteno sis in Sweden:a report from the Swedish Coronary Angiography and Angioplasty Registry(SCAAR)[J].Euro Intervention,2013,9(5):564-572.DOI:10.4244/EIJV9I5A92.
• [17] Paramasivam G,Devasia T,Ubaid S,et al.In-stent restenosis of drug-eluting stents:clinical presentation and outcomes in a realworld scenario[J].Egypt Heart J,2019,71(1):28.DOI:10.1186/s43044-019-0025-z.
• [18]Xie H,Qiu M,Li X,et al.Drug-coated balloon angioplasty versus drug-eluting stent implantation in ACS patients with different angiographic patterns of in-stent restenosis[J].Int J Cardiol,2024,415:132450.DOI:10.1016/j.ijcard.2024.132450.
• [19]Nedosugova LV,Markina YV,Bochkareva LA,et al.Inflammatory mechanisms of diabetes and its vascular complications[J].Biomedicines,2022,10(5):1168.DOI:10.3 390/biomedicines10051168.
• [20] Shishido K,Antoniadis AP,Takahashi S,et al.Effects of low endothelial shear stress after stent implantation on subsequent neointimal hyperplasia and clinical outcomes in humans[J].J Am Heart Assoc,2016,5(9):e002949.DOI:10.1161/JAHA.115.002949.
• [21] Wada H,Miyauchi K,Daida H.Gender differences in the clinical features and outcomes of patients with coronary artery disease[J].Expert Rev Cardiovasc Ther,2019,17(2):127-133.DOI:10.1080/14779072.2019.1561277.
• [22]冯欢欢,袁晓航,胡鑫,等.复发性药物洗脱支架内再狭窄的危险因素分析[J].中国介入心脏病学杂志,2024,32(9):489-495.DOI:10.3969/j.issn.1004-8812.2024.09.002.
• [23] Alexandrescu DM,Mitu O,Costache II,et al.Risk factors associated with intra-stent restenosis after percutaneous coronary intervention[J].Exp Ther Med,2021,22(4):1141.DOI:10.3892/etm.2021.10575.
• [24]Kurihara K,Ashikaga T,Sasaoka T,et al.Incidence and predictors of early and late target lesion revascularization after everolimus-eluting stent implantation in unselected patients in Japan[J].Catheter Cardiovasc Interv,2017,90(1):78-86.DOI:10.1002/ccd.26964.
• [25]Medina-Leyte DJ,Zepeda-García O,Domínguez-Pérez M,et al.Endothelial dysfunction,inflammation and coronary artery disease:potential biomarkers and promising therapeutical approaches[J].Int J Mol Sci,2021,22(8):3850.DOI:10.3390/ijms22083850.
• [26]Sugiyama T,Yamamoto E,Fracassi F,et al.Calcified plaques in patients with acute coronary syndromes[J].JACC Cardiovasc Interv,2019,12(6):531-540.DOI:10.1016/j.jcin.2018.12.013.